Global Pernicious Anemia Diagnosis and Treatment Market 2026-2035

Description

List of Tables

Pernicious Anemia Diagnosis and Treatment Market Size, Share & Trends Analysis Report by Diagnosis (Complete Blood Count Test, Vitamin B-12 Deficiency Test, Biopsy, and Intrinsic Factor Deficiency Test), By Treatment (Vitamin B-12 Injections, Vitamin B-12 Pills, and Other), Forecast Period (2026-2035)

Industry Overview

Pernicious anemia diagnosis and treatment market was valued at $1,428.1 million in 2025 and is projected to reach $2,883.0 million by 2035, growing at a CAGR of 6.8% during the forecast period (2026-2035). The global pernicious anemia diagnosis and treatment market is experiencing steady expansion as healthcare systems place greater emphasis on identifying B-12 absorption disorders at an earlier stage. Advances in laboratory techniques and wider access to specialized tests are helping clinicians confirm cases with more certainty, which in turn is increasing the volume of patients entering formal treatment pathways. At the same time, improved awareness among both physicians and patients is leading to quicker recognition of symptoms linked to autoimmune-driven B-12 deficiency. This has encouraged more consistent follow-up care and higher adoption of targeted therapeutic options. Growing attention to long-term management and better clinical outcomes is further strengthening market demand.

Market Dynamics

Rising Adoption of Advanced Diagnostic Assays

The market is witnessing steady growth as healthcare providers increasingly adopt intrinsic-factor antibody tests, parietal-cell antibody assays, and high-precision hematology analyzers for early identification of pernicious anemia. This shift is driven by a stronger clinical focus on accurate differentiation between autoimmune B-12 deficiency and nutritional deficiency. The push toward standardized laboratory workflows and improved diagnostic accuracy is also supporting the broader uptake of advanced testing platforms across hospitals and diagnostic networks.

Growing Preference For Long-Acting And Patient-Friendly B-12 Therapies

Treatment practices are evolving as demand increases for efficient, long-acting vitamin B-12 formulations, including injectable and high-strength oral options. Physicians are recommending sustained-release products to improve patient adherence and reduce the frequency of clinical visits. In parallel, manufacturers are expanding production of reliable and cost-effective B-12 therapies, reinforcing the market's shift toward convenient and outcome-focused treatment solutions.

Market Segmentation

Based on the diagnosis, the market is segmented into complete blood count test, vitamin B-12 deficiency test, biopsy, and intrinsic factor deficiency test.
Based on the treatment, the market is segmented into vitamin B-12 injections, vitamin B-12 pills, and others.

Complete Blood Count Test Segment to Lead the Market with the Largest Share

The increasing dependence on complete blood count testing is contributing meaningfully to the market's expansion. As clinicians rely on CBC results to identify abnormal red cell patterns at an early stage, more cases are being flagged for further evaluation. This routine test has become a practical entry point for diagnosing complex B-12 absorption disorders, allowing physicians to intervene sooner. Its accessibility in primary and tertiary care settings is helping improve diagnostic consistency. With laboratories standardizing their workflows, the volume of CBC-based assessments continues to climb. This steady rise in testing activity is reinforcing the market's overall growth.

Vitamin B-12 Injections: A Key Segment in Market Growth

The wider use of vitamin B-12 injections is strengthening the market as healthcare providers favor therapies that offer reliable absorption and predictable outcomes. These injectable formulations are often recommended when oral routes are insufficient, which makes them a key component of long-term management. Patients receiving timely injections tend to show quicker symptom improvement, prompting physicians to adopt structured treatment schedules. Demand has also increased as clinics focus on minimizing relapse and maintaining stable B-12 levels. Manufacturers are expanding supply to meet this consistent therapeutic need. Together, these factors are supporting robust market momentum.

Regional Outlook

The global pernicious anemia diagnosis and treatment market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Growing Improvements in Clinical Pathways in Europe

The European market is benefiting from improvements in clinical pathways designed to manage chronic B-12 absorption disorders more effectively. Healthcare providers across the region are adopting evidence-based diagnostic methods that help distinguish pernicious anemia from other forms of deficiency. Public health initiatives have raised awareness of the condition, prompting timely consultations and testing. Consistent regulatory oversight ensures high-quality diagnostic reagents and therapeutic products, reinforcing trust among physicians. In addition, expanded access to specialist care is improving long-term monitoring and treatment adherence. Together, these factors are contributing to the market's upward outlook.

North America Region Dominates the Market with a Major Share

The North American market is progressing as healthcare systems enhance their screening practices for autoimmune B-12 deficiencies. Hospitals and diagnostic centers are integrating more refined testing protocols, allowing clinicians to detect complex cases with greater confidence. Rising patient awareness is encouraging individuals to seek evaluation earlier, which is improving treatment initiation rates. Insurance coverage for diagnostic procedures and therapeutic options also supports wider access to care. Pharmaceutical companies in the region continue to introduce reliable formulations that address long-term management needs. These developments collectively strengthen the market's trajectory.

Market Players Outlook

The major companies operating in the global pernicious anemia diagnosis and treatment market include Abbott Laboratories, Danaher Corp. (Beckman Coulter), F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Sysmex Corp., among others. Market players are leveraging partnerships, collaborations, mergers and acquisitions strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

In June 2024, HORIBA, in analytical and measurement technology, expanded its award-winning compact hematology instrument range with the launch of new models with Erythrocyte Sedimentation Rate (ESR) on board. The new Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) now offer combined testing for CBC/DIFF with ESR results from whole blood in 60 seconds, adding a comprehensive profile for inflammatory disease assessment to the instruments' already extensive functionality.
In April 2023, Abbott received US Food and Drug Administration clearance for its advanced Alinity h-series hematology system, paving the way for laboratories throughout the country to run complete blood counts (CBC) as a part of Abbott's Alinity family of diagnostic products. Complete blood counts are one of the most ordered tests in the healthcare system and are common in routine checkups because they can help screen for a variety of disorders, including infections, anemia, diseases of the immune system, and blood cancers.

The Report Covers:

Market value data analysis of 2025 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global pernicious anemia diagnosis and treatment market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2023738

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Pernicious Anemia Diagnosis and Treatment Market Sales Analysis - Diagnosis | Treatment | ($ Million)
Pernicious Anemia Diagnosis and Treatment Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Pernicious Anemia Diagnosis and Treatment Market Trends
- 2.2.2. Market Recommendations
2.3. Porter's Five Forces Analysis for the Pernicious Anemia Diagnosis and Treatment Market
- 2.3.1. Competitive Rivalry
- 2.3.2. Threat of New Entrants
- 2.3.3. Bargaining Power of Suppliers
- 2.3.4. Bargaining Power of Buyers
- 2.3.5. Threat of Substitutes

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Pernicious Anemia Diagnosis and Treatment Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Pernicious Anemia Diagnosis and Treatment Market: Impact Analysis
3.3. Market Opportunities

4. Competitive Landscape

4.1. Competitive Dashboard - Pernicious Anemia Diagnosis and Treatment Market Revenue and Share by Manufacturers
Pernicious Anemia Diagnosis and Treatment Product Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Abbott Laboratories
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Danaher Corp. (Beckman Coulter)
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. F. Hoffmann-La Roche Ltd.
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Siemens Healthineers AG
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Sysmex Corp.
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global Pernicious Anemia Diagnosis and Treatment Market Sales Analysis by Diagnosis ($ Million)

5.1. Complete Blood Count Test
5.2. Vitamin B-12 Deficiency Test
5.3. Biopsy
5.4. Intrinsic Factor Deficiency Test

6. Global Pernicious Anemia Diagnosis and Treatment Market Sales Analysis by Treatment ($ Million)

6.1. Vitamin B-12 Injections
6.2. Vitamin B-12 Pills
6.3. Other (Spray)

7. Regional Analysis

7.1. North American Pernicious Anemia Diagnosis and Treatment Market Sales Analysis - Diagnosis | Treatment | Country ($ Million)
Macroeconomic Factors for North America
- 7.1.1. United States
- 7.1.2. Canada
7.2. European Pernicious Anemia Diagnosis and Treatment Market Sales Analysis - Diagnosis | Treatment | Country ($ Million)
Macroeconomic Factors for Europe
- 7.2.1. UK
- 7.2.2. Germany
- 7.2.3. Italy
- 7.2.4. Spain
- 7.2.5. France
- 7.2.6. Russia
- 7.2.7. Rest of Europe
7.3. Asia-Pacific Pernicious Anemia Diagnosis and Treatment Market Sales Analysis - Diagnosis | Treatment | Country ($ Million)
Macroeconomic Factors for Asia-Pacific
- 7.3.1. China
- 7.3.2. Japan
- 7.3.3. South Korea
- 7.3.4. India
- 7.3.5. Australia & New Zealand
- 7.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 7.3.7. Rest of Asia-Pacific
7.4. Rest of the World Pernicious Anemia Diagnosis and Treatment Market Sales Analysis - Diagnosis | Treatment | Country ($ Million)
Macroeconomic Factors for Rest of the World
- 7.4.1. Latin America
- 7.4.2. Middle East and Africa

8. Company Profiles

8.1. Abbott Laboratories
- 8.1.1. Quick Facts
- 8.1.2. Company Overview
- 8.1.3. Product Portfolio
- 8.1.4. Business Strategies
8.2. Bio-Rad Laboratories, Inc.
- 8.2.1. Quick Facts
- 8.2.2. Company Overview
- 8.2.3. Product Portfolio
- 8.2.4. Business Strategies
8.3. Cipla Ltd.
- 8.3.1. Quick Facts
- 8.3.2. Company Overview
- 8.3.3. Product Portfolio
- 8.3.4. Business Strategies
8.4. Danaher Corp. (Beckman Coulter)
- 8.4.1. Quick Facts
- 8.4.2. Company Overview
- 8.4.3. Product Portfolio
- 8.4.4. Business Strategies
8.5. F. Hoffmann-La Roche Ltd. (Roche Diagnostics)
- 8.5.1. Quick Facts
- 8.5.2. Company Overview
- 8.5.3. Product Portfolio
- 8.5.4. Business Strategies
8.6. Fresenius Kabi AG
- 8.6.1. Quick Facts
- 8.6.2. Company Overview
- 8.6.3. Product Portfolio
- 8.6.4. Business Strategies
8.7. GlaxoSmithKline plc (GSK)
- 8.7.1. Quick Facts
- 8.7.2. Company Overview
- 8.7.3. Product Portfolio
- 8.7.4. Business Strategies
8.8. Hikma Pharmaceuticals PLC
- 8.8.1. Quick Facts
- 8.8.2. Company Overview
- 8.8.3. Product Portfolio
- 8.8.4. Business Strategies
8.9. Horiba Ltd.
- 8.9.1. Quick Facts
- 8.9.2. Company Overview
- 8.9.3. Product Portfolio
- 8.9.4. Business Strategies
8.10. Jubilant Life Sciences Ltd.
- 8.10.1. Quick Facts
- 8.10.2. Company Overview
- 8.10.3. Product Portfolio
- 8.10.4. Business Strategies
8.11. Mindray Medical International Ltd.
- 8.11.1. Quick Facts
- 8.11.2. Company Overview
- 8.11.3. Product Portfolio
- 8.11.4. Business Strategies
8.12. Ortho Clinical Diagnostics
- 8.12.1. Quick Facts
- 8.12.2. Company Overview
- 8.12.3. Product Portfolio
- 8.12.4. Business Strategies
8.13. Pfizer Inc.
- 8.13.1. Quick Facts
- 8.13.2. Company Overview
- 8.13.3. Product Portfolio
- 8.13.4. Business Strategies
8.14. Sandoz International GmbH (Novartis division)
- 8.14.1. Quick Facts
- 8.14.2. Company Overview
- 8.14.3. Product Portfolio
- 8.14.4. Business Strategies
8.15. Siemens Healthineers AG
- 8.15.1. Quick Facts
- 8.15.2. Company Overview
- 8.15.3. Product Portfolio
- 8.15.4. Business Strategies
8.16. Sun Pharmaceutical Industries Ltd.
- 8.16.1. Quick Facts
- 8.16.2. Company Overview
- 8.16.3. Product Portfolio
- 8.16.4. Business Strategies
8.17. Sysmex Corp.
- 8.17.1. Quick Facts
- 8.17.2. Company Overview
- 8.17.3. Product Portfolio
- 8.17.4. Business Strategies
8.18. Teva Pharmaceutical Industries Ltd.
- 8.18.1. Quick Facts
- 8.18.2. Company Overview
- 8.18.3. Product Portfolio
- 8.18.4. Business Strategies
8.19. Thermo Fisher Scientific Inc.
- 8.19.1. Quick Facts
- 8.19.2. Company Overview
- 8.19.3. Product Portfolio
- 8.19.4. Business Strategies
8.20. Viatris Inc. (Mylan)
- 8.20.1. Quick Facts
- 8.20.2. Company Overview
- 8.20.3. Product Portfolio
- 8.20.4. Business Strategies